Skip to content
Dx

FY2027 · effective October 1, 2026

What changed in ICD-10 for 2027

Claims with dates of service on or after October 1, 2026 must use the FY2027 code set. Here is every code that was added, retitled or removed this year.
238new diagnosis4revised diagnosis21deleted diagnosis186new procedure2revised procedure41deleted procedure

New ICD-10-CM diagnosis codes (238)

  • C78.31Secondary malignant neoplasm of larynx
  • C78.32Secondary malignant neoplasm of pharynx
  • C79.83Secondary malignant neoplasm of oral cavity
  • D69.11Glanzmann thrombasthenia
  • D69.19Other qualitative platelet defects
  • E89.83Postprocedural hypoglycemia following a procedure
  • E89.830Post bariatric hypoglycemia
  • E89.838Other postprocedural hypoglycemia
  • F64.AGender identity disorder, in remission
  • I42.00Dilated cardiomyopathy, unspecified
  • I42.01Familial-genetic dilated cardiomyopathy
  • I42.09Other dilated cardiomyopathy
  • I42.81Arrhythmogenic cardiomyopathy
  • I42.89Other cardiomyopathies not elsewhere classified
  • I47.22Catecholaminergic polymorphic ventricular tachycardia [CPVT]
  • I49.81Brugada syndrome
  • I49.82Ventricular bigeminy
  • I49.89Other specified cardiac arrhythmias not elsewhere classified
  • J34.83Odontogenic sinusitis
  • J34.830Odontogenic sinusitis, maxillary sinus
  • J34.831Odontogenic sinusitis, ethmoid sinus
  • J34.832Odontogenic sinusitis, frontal sinus
  • J34.833Odontogenic sinusitis, sphenoid sinus
  • J34.839Odontogenic sinusitis, unspecified
  • J4BPulmonary mycetoma
  • K31.BHypertrophic pyloric stenosis, in childhood
  • K6ADiseases of the pelvis, not elsewhere classified
  • K6A.0Pelvic abscess
  • K6A.01Prevesical abscess
  • K6A.09Other pelvic abscess
  • K6A.8Other diseases of the pelvis, not elsewhere classified
  • K74.0AHepatic fibrosis, moderate fibrosis
  • K76.83Intestinal failure-associated liver disease
  • L02.237Carbuncle of flank
  • M04.3VEXAS syndrome
  • M67.APlantar fasciitis
  • M67.A0Plantar fasciitis, foot
  • M67.A01Plantar fasciitis, right foot
  • M67.A02Plantar fasciitis, left foot
  • M67.A09Plantar fasciitis, unspecified foot
  • M72.20Plantar fascial fibromatosis, unspecified foot
  • M72.21Plantar fascial fibromatosis, right foot
  • M72.22Plantar fascial fibromatosis, left foot
  • M86.8X11Other osteomyelitis, right shoulder
  • M86.8X12Other osteomyelitis, left shoulder
  • M86.8X19Other osteomyelitis, unspecified shoulder
  • M86.8X21Other osteomyelitis, right upper arm
  • M86.8X22Other osteomyelitis, left upper arm
  • M86.8X29Other osteomyelitis, unspecified upper arm
  • M86.8X31Other osteomyelitis, right forearm
  • M86.8X32Other osteomyelitis, left forearm
  • M86.8X39Other osteomyelitis, unspecified forearm
  • M86.8X41Other osteomyelitis, right hand
  • M86.8X42Other osteomyelitis, left hand
  • M86.8X49Other osteomyelitis, unspecified hand
  • M86.8X51Other osteomyelitis, right thigh
  • M86.8X52Other osteomyelitis, left thigh
  • M86.8X59Other osteomyelitis, unspecified thigh
  • M86.8X61Other osteomyelitis, right lower leg
  • M86.8X62Other osteomyelitis, left lower leg
  • M86.8X69Other osteomyelitis, unspecified lower leg
  • M86.8X71Other osteomyelitis, right ankle and foot
  • M86.8X72Other osteomyelitis, left ankle and foot
  • M86.8X79Other osteomyelitis, unspecified ankle and foot
  • M86.8X80Other osteomyelitis, skull
  • M86.8X81Other osteomyelitis, face and sinuses
  • M86.8X89Other osteomyelitis, other site
  • N99.86Intraoperative and postprocedural complications and disorders of breast
  • N99.860Intraoperative and postprocedural nipple ischemia
  • N99.861Intraoperative and postprocedural nipple necrosis
  • O00.12Interstitial ectopic pregnancy without intrauterine pregnancy
  • O00.121Right interstitial ectopic pregnancy without intrauterine pregnancy
  • O00.122Left interstitial ectopic pregnancy without intrauterine pregnancy
  • O00.129Unspecified interstitial ectopic pregnancy without intrauterine pregnancy
  • O00.13Interstitial ectopic pregnancy with intrauterine pregnancy
  • O00.131Right interstitial ectopic pregnancy with intrauterine pregnancy
  • O00.132Left interstitial ectopic pregnancy with intrauterine pregnancy
  • O00.139Unspecified interstitial ectopic pregnancy with intrauterine pregnancy
  • O00.3Cesarean scar ectopic pregnancy
  • O00.31Cesarean scar ectopic pregnancy without intrauterine pregnancy
  • O00.32Cesarean scar ectopic pregnancy with intrauterine pregnancy
  • O00.4Cervical ectopic pregnancy
  • O00.41Cervical ectopic pregnancy without intrauterine pregnancy
  • O00.42Cervical ectopic pregnancy with intrauterine pregnancy
  • O00.5Cornual ectopic pregnancy
  • O00.51Cornual ectopic pregnancy without intrauterine pregnancy
  • O00.511Right cornual ectopic pregnancy without intrauterine pregnancy
  • O00.512Left cornual ectopic pregnancy without intrauterine pregnancy
  • O00.519Unspecified cornual ectopic pregnancy without intrauterine pregnancy
  • O00.52Cornual ectopic pregnancy with intrauterine pregnancy
  • O00.521Right cornual ectopic pregnancy with intrauterine pregnancy
  • O00.522Left cornual ectopic pregnancy with intrauterine pregnancy
  • O00.529Unspecified cornual ectopic pregnancy with intrauterine pregnancy
  • O31.4Continuing pregnancy after vanishing twin syndrome of one fetus or more
  • O31.40Continuing pregnancy after vanishing twin syndrome of one fetus or more, unspecified trimester
  • O31.40X0Continuing pregnancy after vanishing twin syndrome of one fetus or more, unspecified trimester, not applicable or unspecified
  • O31.40X1Continuing pregnancy after vanishing twin syndrome of one fetus or more, unspecified trimester, fetus 1
  • O31.40X2Continuing pregnancy after vanishing twin syndrome of one fetus or more, unspecified trimester, fetus 2
  • O31.40X3Continuing pregnancy after vanishing twin syndrome of one fetus or more, unspecified trimester, fetus 3
  • O31.40X4Continuing pregnancy after vanishing twin syndrome of one fetus or more, unspecified trimester, fetus 4
  • O31.40X5Continuing pregnancy after vanishing twin syndrome of one fetus or more, unspecified trimester, fetus 5
  • O31.40X9Continuing pregnancy after vanishing twin syndrome of one fetus or more, unspecified trimester, other fetus
  • O31.41Continuing pregnancy after vanishing twin syndrome of one fetus or more, first trimester
  • O31.41X0Continuing pregnancy after vanishing twin syndrome of one fetus or more, first trimester, not applicable or unspecified
  • O31.41X1Continuing pregnancy after vanishing twin syndrome of one fetus or more, first trimester, fetus 1
  • O31.41X2Continuing pregnancy after vanishing twin syndrome of one fetus or more, first trimester, fetus 2
  • O31.41X3Continuing pregnancy after vanishing twin syndrome of one fetus or more, first trimester, fetus 3
  • O31.41X4Continuing pregnancy after vanishing twin syndrome of one fetus or more, first trimester, fetus 4
  • O31.41X5Continuing pregnancy after vanishing twin syndrome of one fetus or more, first trimester, fetus 5
  • O31.41X9Continuing pregnancy after vanishing twin syndrome of one fetus or more, first trimester, other fetus
  • O31.42Continuing pregnancy after vanishing twin syndrome of one fetus or more, second trimester
  • O31.42X0Continuing pregnancy after vanishing twin syndrome of one fetus or more, second trimester, not applicable or unspecified
  • O31.42X1Continuing pregnancy after vanishing twin syndrome of one fetus or more, second trimester, fetus 1
  • O31.42X2Continuing pregnancy after vanishing twin syndrome of one fetus or more, second trimester, fetus 2
  • O31.42X3Continuing pregnancy after vanishing twin syndrome of one fetus or more, second trimester, fetus 3
  • O31.42X4Continuing pregnancy after vanishing twin syndrome of one fetus or more, second trimester, fetus 4
  • O31.42X5Continuing pregnancy after vanishing twin syndrome of one fetus or more, second trimester, fetus 5
  • O31.42X9Continuing pregnancy after vanishing twin syndrome of one fetus or more, second trimester, other fetus
  • O31.43Continuing pregnancy after vanishing twin syndrome of one fetus or more, third trimester
  • O31.43X0Continuing pregnancy after vanishing twin syndrome of one fetus or more, third trimester, not applicable or unspecified
  • O31.43X1Continuing pregnancy after vanishing twin syndrome of one fetus or more, third trimester, fetus 1
  • O31.43X2Continuing pregnancy after vanishing twin syndrome of one fetus or more, third trimester, fetus 2
  • O31.43X3Continuing pregnancy after vanishing twin syndrome of one fetus or more, third trimester, fetus 3
  • O31.43X4Continuing pregnancy after vanishing twin syndrome of one fetus or more, third trimester, fetus 4
  • O31.43X5Continuing pregnancy after vanishing twin syndrome of one fetus or more, third trimester, fetus 5
  • O31.43X9Continuing pregnancy after vanishing twin syndrome of one fetus or more, third trimester, other fetus
  • Q87.ALoeys-Dietz syndrome
  • QA1Genetic disorders associated with neoplasms, not elsewhere classified
  • QA1.7Inherited neoplasm predisposition syndromes involving multiple systems, not elsewhere classified
  • QA1.71Lynch syndrome
  • QA1.79Other inherited neoplasm predisposition syndrome of multiple systems
  • QA1.790Familial cancer syndrome with pathogenic BRCA1 mutation
  • QA1.791Familial cancer syndrome with pathogenic BRCA2 mutation
  • QA1.792Li Fraumeni syndrome
  • QA1.798Other inherited neoplasm predisposition syndrome of multiple systems
  • R78.72Abnormal gadolinium level in blood
  • T52.81Toxic effects of alkenes
  • T52.811Toxic effect of alkenes, accidental (unintentional)
  • T52.811AToxic effect of alkenes, accidental (unintentional), initial encounter
  • T52.811DToxic effect of alkenes, accidental (unintentional), subsequent encounter
  • T52.811SToxic effect of alkenes, accidental (unintentional), sequela
  • T52.812Toxic effect of alkenes, intentional self-harm
  • T52.812AToxic effect of alkenes, intentional self-harm, initial encounter
  • T52.812DToxic effect of alkenes, intentional self-harm, subsequent encounter
  • T52.812SToxic effect of alkenes, intentional self-harm, sequela
  • T52.813Toxic effect of alkenes, assault
  • T52.813AToxic effect of alkenes, assault, initial encounter
  • T52.813DToxic effect of alkenes, assault, subsequent encounter
  • T52.813SToxic effect of alkenes, assault, sequela
  • T52.814Toxic effect of alkenes, undetermined
  • T52.814AToxic effect of alkenes, undetermined, initial encounter
  • T52.814DToxic effect of alkenes, undetermined, subsequent encounter
  • T52.814SToxic effect of alkenes, undetermined, sequela
  • T52.82Toxic effects of cycloparaffins
  • T52.821Toxic effect of cycloparaffins, accidental (unintentional)
  • T52.821AToxic effect of cycloparaffins, accidental (unintentional), initial encounter
  • T52.821DToxic effect of cycloparaffins, accidental (unintentional), subsequent encounter
  • T52.821SToxic effect of cycloparaffins, accidental (unintentional), sequela
  • T52.822Toxic effect of cycloparaffins, intentional self-harm
  • T52.822AToxic effect of cycloparaffins, intentional self-harm, initial encounter
  • T52.822DToxic effect of cycloparaffins, intentional self-harm, subsequent encounter
  • T52.822SToxic effect of cycloparaffins, intentional self-harm, sequela
  • T52.823Toxic effect of cycloparaffins, assault
  • T52.823AToxic effect of cycloparaffins, assault, initial encounter
  • T52.823DToxic effect of cycloparaffins, assault, subsequent encounter
  • T52.823SToxic effect of cycloparaffins, assault, sequela
  • T52.824Toxic effect of cycloparaffins, undetermined
  • T52.824AToxic effect of cycloparaffins, undetermined, initial encounter
  • T52.824DToxic effect of cycloparaffins, undetermined, subsequent encounter
  • T52.824SToxic effect of cycloparaffins, undetermined, sequela
  • T52.89Toxic effects of other organic solvents
  • T52.891Toxic effect of other organic solvents, accidental (unintentional)
  • T52.891AToxic effect of other organic solvents, accidental (unintentional), initial encounter
  • T52.891DToxic effect of other organic solvents, accidental (unintentional), subsequent encounter
  • T52.891SToxic effect of other organic solvents, accidental (unintentional), sequela
  • T52.892Toxic effect of other organic solvents, intentional self-harm
  • T52.892AToxic effect of other organic solvents, intentional self-harm, initial encounter
  • T52.892DToxic effect of other organic solvents, intentional self-harm, subsequent encounter
  • T52.892SToxic effect of other organic solvents, intentional self-harm, sequela
  • T52.893Toxic effect of other organic solvents, assault
  • T52.893AToxic effect of other organic solvents, assault, initial encounter
  • T52.893DToxic effect of other organic solvents, assault, subsequent encounter
  • T52.893SToxic effect of other organic solvents, assault, sequela
  • T52.894Toxic effect of other organic solvents, undetermined
  • T52.894AToxic effect of other organic solvents, undetermined, initial encounter
  • T52.894DToxic effect of other organic solvents, undetermined, subsequent encounter
  • T52.894SToxic effect of other organic solvents, undetermined, sequela
  • T59.82Toxic effects of hexamethylene diisocyanate
  • T59.821Toxic effect of hexamethylene diisocyanate, accidental (unintentional)
  • T59.821AToxic effect of hexamethylene diisocyanate, accidental (unintentional), initial encounter
  • T59.821DToxic effect of hexamethylene diisocyanate, accidental (unintentional), subsequent encounter
  • T59.821SToxic effect of hexamethylene diisocyanate, accidental (unintentional), sequela
  • T59.822Toxic effect of hexamethylene diisocyanate, intentional self-harm
  • T59.822AToxic effect of hexamethylene diisocyanate, intentional self-harm, initial encounter
  • T59.822DToxic effect of hexamethylene diisocyanate, intentional self-harm, subsequent encounter
  • T59.822SToxic effect of hexamethylene diisocyanate, intentional self-harm, sequela
  • T59.823Toxic effect of hexamethylene diisocyanate, assault
  • T59.823AToxic effect of hexamethylene diisocyanate, assault, initial encounter
  • T59.823DToxic effect of hexamethylene diisocyanate, assault, subsequent encounter
  • T59.823SToxic effect of hexamethylene diisocyanate, assault, sequela
  • T59.824Toxic effect of hexamethylene diisocyanate, undetermined
  • T59.824AToxic effect of hexamethylene diisocyanate, undetermined, initial encounter
  • T59.824DToxic effect of hexamethylene diisocyanate, undetermined, subsequent encounter
  • T59.824SToxic effect of hexamethylene diisocyanate, undetermined, sequela
  • T65.85Toxic effect of medetomidine
  • T65.851Toxic effect of medetomidine, accidental (unintentional)
  • T65.851AToxic effect of medetomidine, accidental (unintentional), initial encounter
  • T65.851DToxic effect of medetomidine, accidental (unintentional), subsequent encounter
  • T65.851SToxic effect of medetomidine, accidental (unintentional), sequela
  • T65.852Toxic effect of medetomidine, intentional self-harm
  • T65.852AToxic effect of medetomidine, intentional self-harm, initial encounter
  • T65.852DToxic effect of medetomidine, intentional self-harm, subsequent encounter
  • T65.852SToxic effect of medetomidine, intentional self-harm, sequela
  • T65.853Toxic effect of medetomidine, assault
  • T65.853AToxic effect of medetomidine, assault, initial encounter
  • T65.853DToxic effect of medetomidine, assault, subsequent encounter
  • T65.853SToxic effect of medetomidine, assault, sequela
  • T65.854Toxic effect of medetomidine, undetermined
  • T65.854AToxic effect of medetomidine, undetermined, initial encounter
  • T65.854DToxic effect of medetomidine, undetermined, subsequent encounter
  • T65.854SToxic effect of medetomidine, undetermined, sequela
  • Z68.18Body mass index [BMI] 18.4 or less, adult
  • Z68.19Body mass index [BMI] 18.5-19.9, adult
  • Z77.013Contact with and (suspected) exposure to gadolinium
  • Z77.32Contact with and (suspected) exposure to burn pits in war theater
  • Z77.33Contact with and (suspected) exposure to Agent Orange
  • Z77.4Contact with and (suspected) exposure to blast overpressure
  • Z77.40Contact with and (suspected) exposure to unspecified blast overpressure
  • Z77.41Contact with and (suspected) exposure to low-level blast overpressure
  • Z77.42Contact with and (suspected) exposure to high-level blast overpressure
  • Z77.49Contact with and (suspected) exposure to other blast overpressure
  • Z86.17Personal history of Clostridioides difficile infection
  • Z87.8901Personal history of social gender transition
  • Z87.8902Personal history of medical gender transition
  • Z87.8903Personal history of surgical gender transition
  • Z87.8904Personal history of intersex surgery
  • Z87.8909Personal history of unspecified gender transition
  • Z87.893Personal history of gender detransition

Revised ICD-10-CM diagnosis codes (4)

  • L02.232Carbuncle of back [any part, except buttock and flank]Was: Carbuncle of back [any part, except buttock]
  • L03.312Cellulitis of back [any part except buttock and flank]Was: Cellulitis of back [any part except buttock]
  • L03.322Acute lymphangitis of back [any part except buttock and flank]Was: Acute lymphangitis of back [any part except buttock]
  • Z29.14Encounter for prophylactic rabies immune globulinWas: Encounter for prophylactic rabies immune globin

Deleted ICD-10-CM diagnosis codes (21)

  • S23.420Sprain of sternoclavicular (joint) (ligament)
  • S23.420ASprain of sternoclavicular (joint) (ligament), initial encounter
  • S23.420DSprain of sternoclavicular (joint) (ligament), subsequent encounter
  • S23.420SSprain of sternoclavicular (joint) (ligament), sequela
  • T52.8XToxic effects of other organic solvents
  • T52.8X1Toxic effect of other organic solvents, accidental (unintentional)
  • T52.8X1AToxic effect of other organic solvents, accidental (unintentional), initial encounter
  • T52.8X1DToxic effect of other organic solvents, accidental (unintentional), subsequent encounter
  • T52.8X1SToxic effect of other organic solvents, accidental (unintentional), sequela
  • T52.8X2Toxic effect of other organic solvents, intentional self-harm
  • T52.8X2AToxic effect of other organic solvents, intentional self-harm, initial encounter
  • T52.8X2DToxic effect of other organic solvents, intentional self-harm, subsequent encounter
  • T52.8X2SToxic effect of other organic solvents, intentional self-harm, sequela
  • T52.8X3Toxic effect of other organic solvents, assault
  • T52.8X3AToxic effect of other organic solvents, assault, initial encounter
  • T52.8X3DToxic effect of other organic solvents, assault, subsequent encounter
  • T52.8X3SToxic effect of other organic solvents, assault, sequela
  • T52.8X4Toxic effect of other organic solvents, undetermined
  • T52.8X4AToxic effect of other organic solvents, undetermined, initial encounter
  • T52.8X4DToxic effect of other organic solvents, undetermined, subsequent encounter
  • T52.8X4SToxic effect of other organic solvents, undetermined, sequela

New ICD-10-PCS procedure codes (186)

  • 028F3Z0Division of Aortic Valve, Percutaneous Approach, Native Leaflet
  • 028F3Z1Division of Aortic Valve, Percutaneous Approach, Prosthetic Leaflet
  • 028G3Z0Division of Mitral Valve, Percutaneous Approach, Native Leaflet
  • 028G3Z1Division of Mitral Valve, Percutaneous Approach, Prosthetic Leaflet
  • 02HM3JZInsertion of Pacemaker Lead into Ventricular Septum, Percutaneous Approach
  • 02HM3KZInsertion of Defibrillator Lead into Ventricular Septum, Percutaneous Approach
  • 02HM3MZInsertion of Cardiac Lead into Ventricular Septum, Percutaneous Approach
  • 02HM3NZInsertion of Intracardiac Pacemaker into Ventricular Septum, Percutaneous Approach
  • 02HM3YZInsertion of Other Device into Ventricular Septum, Percutaneous Approach
  • 0DDU0ZZExtraction of Omentum, Open Approach
  • 0DDU4ZZExtraction of Omentum, Percutaneous Endoscopic Approach
  • 0DDV0ZZExtraction of Mesentery, Open Approach
  • 0DDV4ZZExtraction of Mesentery, Percutaneous Endoscopic Approach
  • 0F9480DDrainage of Gallbladder with Drainage Device, Via Natural or Artificial Opening Endoscopic, Transmural
  • 0F9480EDrainage of Gallbladder with Drainage Device, Via Natural or Artificial Opening Endoscopic, Transpapillary
  • 0F9580DDrainage of Right Hepatic Duct with Drainage Device, Via Natural or Artificial Opening Endoscopic, Transmural
  • 0F9580EDrainage of Right Hepatic Duct with Drainage Device, Via Natural or Artificial Opening Endoscopic, Transpapillary
  • 0F9680DDrainage of Left Hepatic Duct with Drainage Device, Via Natural or Artificial Opening Endoscopic, Transmural
  • 0F9680EDrainage of Left Hepatic Duct with Drainage Device, Via Natural or Artificial Opening Endoscopic, Transpapillary
  • 0F9780DDrainage of Common Hepatic Duct with Drainage Device, Via Natural or Artificial Opening Endoscopic, Transmural
  • 0F9780EDrainage of Common Hepatic Duct with Drainage Device, Via Natural or Artificial Opening Endoscopic, Transpapillary
  • 0F9880DDrainage of Cystic Duct with Drainage Device, Via Natural or Artificial Opening Endoscopic, Transmural
  • 0F9880EDrainage of Cystic Duct with Drainage Device, Via Natural or Artificial Opening Endoscopic, Transpapillary
  • 0F9980DDrainage of Common Bile Duct with Drainage Device, Via Natural or Artificial Opening Endoscopic, Transmural
  • 0F9980EDrainage of Common Bile Duct with Drainage Device, Via Natural or Artificial Opening Endoscopic, Transpapillary
  • 0F9C80DDrainage of Ampulla of Vater with Drainage Device, Via Natural or Artificial Opening Endoscopic, Transmural
  • 0F9C80EDrainage of Ampulla of Vater with Drainage Device, Via Natural or Artificial Opening Endoscopic, Transpapillary
  • 0F9D80DDrainage of Pancreatic Duct with Drainage Device, Via Natural or Artificial Opening Endoscopic, Transmural
  • 0F9D80EDrainage of Pancreatic Duct with Drainage Device, Via Natural or Artificial Opening Endoscopic, Transpapillary
  • 0F9F80DDrainage of Accessory Pancreatic Duct with Drainage Device, Via Natural or Artificial Opening Endoscopic, Transmural
  • 0F9F80EDrainage of Accessory Pancreatic Duct with Drainage Device, Via Natural or Artificial Opening Endoscopic, Transpapillary
  • 0F9G80DDrainage of Pancreas with Drainage Device, Via Natural or Artificial Opening Endoscopic, Transmural
  • 0F9G80EDrainage of Pancreas with Drainage Device, Via Natural or Artificial Opening Endoscopic, Transpapillary
  • 0RGA0E0Fusion of Thoracolumbar Vertebral Joint with Interbody Fusion Device, Custom-Made Anatomically and Virtually Designed, Anterior Approach, Anterior Column, Open Approach
  • 0RGA0EJFusion of Thoracolumbar Vertebral Joint with Interbody Fusion Device, Custom-Made Anatomically and Virtually Designed, Posterior Approach, Anterior Column, Open Approach
  • 0RGA3E0Fusion of Thoracolumbar Vertebral Joint with Interbody Fusion Device, Custom-Made Anatomically and Virtually Designed, Anterior Approach, Anterior Column, Percutaneous Approach
  • 0RGA3EJFusion of Thoracolumbar Vertebral Joint with Interbody Fusion Device, Custom-Made Anatomically and Virtually Designed, Posterior Approach, Anterior Column, Percutaneous Approach
  • 0RGA4E0Fusion of Thoracolumbar Vertebral Joint with Interbody Fusion Device, Custom-Made Anatomically and Virtually Designed, Anterior Approach, Anterior Column, Percutaneous Endoscopic Approach
  • 0RGA4EJFusion of Thoracolumbar Vertebral Joint with Interbody Fusion Device, Custom-Made Anatomically and Virtually Designed, Posterior Approach, Anterior Column, Percutaneous Endoscopic Approach
  • 0SG00E0Fusion of Lumbar Vertebral Joint with Interbody Fusion Device, Custom-Made Anatomically and Virtually Designed, Anterior Approach, Anterior Column, Open Approach
  • 0SG00EJFusion of Lumbar Vertebral Joint with Interbody Fusion Device, Custom-Made Anatomically and Virtually Designed, Posterior Approach, Anterior Column, Open Approach
  • 0SG03E0Fusion of Lumbar Vertebral Joint with Interbody Fusion Device, Custom-Made Anatomically and Virtually Designed, Anterior Approach, Anterior Column, Percutaneous Approach
  • 0SG03EJFusion of Lumbar Vertebral Joint with Interbody Fusion Device, Custom-Made Anatomically and Virtually Designed, Posterior Approach, Anterior Column, Percutaneous Approach
  • 0SG04E0Fusion of Lumbar Vertebral Joint with Interbody Fusion Device, Custom-Made Anatomically and Virtually Designed, Anterior Approach, Anterior Column, Percutaneous Endoscopic Approach
  • 0SG04EJFusion of Lumbar Vertebral Joint with Interbody Fusion Device, Custom-Made Anatomically and Virtually Designed, Posterior Approach, Anterior Column, Percutaneous Endoscopic Approach
  • 0SG10E0Fusion of 2 or more Lumbar Vertebral Joints with Interbody Fusion Device, Custom-Made Anatomically and Virtually Designed, Anterior Approach, Anterior Column, Open Approach
  • 0SG10EJFusion of 2 or more Lumbar Vertebral Joints with Interbody Fusion Device, Custom-Made Anatomically and Virtually Designed, Posterior Approach, Anterior Column, Open Approach
  • 0SG13E0Fusion of 2 or more Lumbar Vertebral Joints with Interbody Fusion Device, Custom-Made Anatomically and Virtually Designed, Anterior Approach, Anterior Column, Percutaneous Approach
  • 0SG13EJFusion of 2 or more Lumbar Vertebral Joints with Interbody Fusion Device, Custom-Made Anatomically and Virtually Designed, Posterior Approach, Anterior Column, Percutaneous Approach
  • 0SG14E0Fusion of 2 or more Lumbar Vertebral Joints with Interbody Fusion Device, Custom-Made Anatomically and Virtually Designed, Anterior Approach, Anterior Column, Percutaneous Endoscopic Approach
  • 0SG14EJFusion of 2 or more Lumbar Vertebral Joints with Interbody Fusion Device, Custom-Made Anatomically and Virtually Designed, Posterior Approach, Anterior Column, Percutaneous Endoscopic Approach
  • 0SG30E0Fusion of Lumbosacral Joint with Interbody Fusion Device, Custom-Made Anatomically and Virtually Designed, Anterior Approach, Anterior Column, Open Approach
  • 0SG30EJFusion of Lumbosacral Joint with Interbody Fusion Device, Custom-Made Anatomically and Virtually Designed, Posterior Approach, Anterior Column, Open Approach
  • 0SG33E0Fusion of Lumbosacral Joint with Interbody Fusion Device, Custom-Made Anatomically and Virtually Designed, Anterior Approach, Anterior Column, Percutaneous Approach
  • 0SG33EJFusion of Lumbosacral Joint with Interbody Fusion Device, Custom-Made Anatomically and Virtually Designed, Posterior Approach, Anterior Column, Percutaneous Approach
  • 0SG34E0Fusion of Lumbosacral Joint with Interbody Fusion Device, Custom-Made Anatomically and Virtually Designed, Anterior Approach, Anterior Column, Percutaneous Endoscopic Approach
  • 0SG34EJFusion of Lumbosacral Joint with Interbody Fusion Device, Custom-Made Anatomically and Virtually Designed, Posterior Approach, Anterior Column, Percutaneous Endoscopic Approach
  • 0TXUrinary System, Transfer
  • 0TXB0Z6Transfer Bladder to Right Ureter, Open Approach
  • 0TXB0Z7Transfer Bladder to Left Ureter, Open Approach
  • 0TXB4Z6Transfer Bladder to Right Ureter, Percutaneous Endoscopic Approach
  • 0TXB4Z7Transfer Bladder to Left Ureter, Percutaneous Endoscopic Approach
  • 0VT00ZEResection of Prostate, Open Approach, Capsule Intact
  • 0VT04ZEResection of Prostate, Percutaneous Endoscopic Approach, Capsule Intact
  • 0VT07ZEResection of Prostate, Via Natural or Artificial Opening, Capsule Intact
  • 0VT08ZEResection of Prostate, Via Natural or Artificial Opening Endoscopic, Capsule Intact
  • 0W99003Drainage of Right Pleural Cavity with Drainage Device, Active Mechanical Clearance, Open Approach
  • 0W99303Drainage of Right Pleural Cavity with Drainage Device, Active Mechanical Clearance, Percutaneous Approach
  • 0W99403Drainage of Right Pleural Cavity with Drainage Device, Active Mechanical Clearance, Percutaneous Endoscopic Approach
  • 0W9B003Drainage of Left Pleural Cavity with Drainage Device, Active Mechanical Clearance, Open Approach
  • 0W9B303Drainage of Left Pleural Cavity with Drainage Device, Active Mechanical Clearance, Percutaneous Approach
  • 0W9B403Drainage of Left Pleural Cavity with Drainage Device, Active Mechanical Clearance, Percutaneous Endoscopic Approach
  • 0W9C003Drainage of Mediastinum with Drainage Device, Active Mechanical Clearance, Open Approach
  • 0W9C303Drainage of Mediastinum with Drainage Device, Active Mechanical Clearance, Percutaneous Approach
  • 0W9C403Drainage of Mediastinum with Drainage Device, Active Mechanical Clearance, Percutaneous Endoscopic Approach
  • 30233S5Transfusion of High-Dose Immune Globulin into Peripheral Vein, Percutaneous Approach
  • 30243S5Transfusion of High-Dose Immune Globulin into Central Vein, Percutaneous Approach
  • 3E00XGFIntroduction of Other Enzymatic/Chemical Agent into Skin and Mucous Membranes, External Approach
  • 3E01XGFIntroduction of Other Enzymatic/Chemical Agent into Subcutaneous Tissue, External Approach
  • 3E033AZIntroduction of Embryonic Stem Cells into Peripheral Vein, Percutaneous Approach
  • 3E043AZIntroduction of Embryonic Stem Cells into Central Vein, Percutaneous Approach
  • 4A0FXEJMeasurement of Musculoskeletal Body Composition using Air Displacement Plethysmography, External Approach
  • 5A0221EAssistance with Cardiac Output using Blood Flow Modulator, Continuous
  • 5A0527DAssistance with Circulatory Decompression using Impeller Pump, Continuous
  • 5A1D701Performance of Urinary Filtration, Intermittent, Less than 6 Hours Per Day, Selective Cytopheresis
  • 5A1D801Performance of Urinary Filtration, Prolonged Intermittent, 6-18 hours Per Day, Selective Cytopheresis
  • 5A1D901Performance of Urinary Filtration, Continuous, Greater than 18 hours Per Day, Selective Cytopheresis
  • B85Imaging, Eye, Other Imaging
  • B85A2ZZOther Imaging of Right Choroid using Fluorescing Agent
  • B85B2ZZOther Imaging of Left Choroid using Fluorescing Agent
  • B85G2ZZOther Imaging of Right Retinal Vessel using Fluorescing Agent
  • B85H2ZZOther Imaging of Left Retinal Vessel using Fluorescing Agent
  • F07DYD0Electrotherapeutic Treatment of Integumentary System - Head and Neck using Microcurrent Stimulation
  • F07EYD0Electrotherapeutic Treatment of Integumentary System - Thorax / Abdomen using Microcurrent Stimulation
  • F07FYD0Electrotherapeutic Treatment of Integumentary System - Upper Back / Upper Extremity using Microcurrent Stimulation
  • F07GYD0Electrotherapeutic Treatment of Integumentary System - Lower Back / Lower Extremity using Microcurrent Stimulation
  • F07HYD0Electrotherapeutic Treatment of Integumentary System - Whole Body using Microcurrent Stimulation
  • F08E5AZWound Management Treatment of Integumentary System - Thorax / Abdomen using Negative Pressure Therapy
  • F08E5BZWound Management Treatment of Integumentary System - Thorax / Abdomen using Physical Agents
  • F08E5CZWound Management Treatment of Integumentary System - Thorax / Abdomen using Mechanical Equipment
  • F08E5DZWound Management Treatment of Integumentary System - Thorax / Abdomen using Electrotherapeutic Equipment
  • F08E5EZWound Management Treatment of Integumentary System - Thorax / Abdomen using Orthosis
  • F08E5FZWound Management Treatment of Integumentary System - Thorax / Abdomen using Assistive, Adaptive, Supportive or Protective Equipment
  • F08E5UZWound Management Treatment of Integumentary System - Thorax / Abdomen using Prosthesis
  • F08E5YZWound Management Treatment of Integumentary System - Thorax / Abdomen using Other Equipment
  • F08E5ZZWound Management Treatment of Integumentary System - Thorax / Abdomen
  • F08P5AZWound Management Treatment of Musculoskeletal System - Thorax / Abdomen using Negative Pressure Therapy
  • F08P5BZWound Management Treatment of Musculoskeletal System - Thorax / Abdomen using Physical Agents
  • F08P5CZWound Management Treatment of Musculoskeletal System - Thorax / Abdomen using Mechanical Equipment
  • F08P5DZWound Management Treatment of Musculoskeletal System - Thorax / Abdomen using Electrotherapeutic Equipment
  • F08P5EZWound Management Treatment of Musculoskeletal System - Thorax / Abdomen using Orthosis
  • F08P5FZWound Management Treatment of Musculoskeletal System - Thorax / Abdomen using Assistive, Adaptive, Supportive or Protective Equipment
  • F08P5UZWound Management Treatment of Musculoskeletal System - Thorax / Abdomen using Prosthesis
  • F08P5YZWound Management Treatment of Musculoskeletal System - Thorax / Abdomen using Other Equipment
  • F08P5ZZWound Management Treatment of Musculoskeletal System - Thorax / Abdomen
  • X0HQ05CInsertion of Leadless Neurostimulator Generator into Vagus Nerve, Open Approach, New Technology Group 12
  • X2723CBDilation of Inferior Vena Cava and Iliocaval Confluence with Open-structure Polymer Lattice Intraluminal Device, Percutaneous Approach, New Technology Group 11
  • X27P3NCDilation of Right Anterior Tibial Artery with Intraluminal Device(s), Small-diameter, Percutaneous Approach, New Technology Group 12
  • X27Q3NCDilation of Left Anterior Tibial Artery with Intraluminal Device(s), Small-diameter, Percutaneous Approach, New Technology Group 12
  • X27R3NCDilation of Right Posterior Tibial Artery with Intraluminal Device(s), Small-diameter, Percutaneous Approach, New Technology Group 12
  • X27S3NCDilation of Left Posterior Tibial Artery with Intraluminal Device(s), Small-diameter, Percutaneous Approach, New Technology Group 12
  • X27T3NCDilation of Right Peroneal Artery with Intraluminal Device(s), Small-diameter, Percutaneous Approach, New Technology Group 12
  • X27U3NCDilation of Left Peroneal Artery with Intraluminal Device(s), Small-diameter, Percutaneous Approach, New Technology Group 12
  • X28M3DCDivision of Ventricular Septum using Transcatheter Septal Scoring Technique, Percutaneous Approach, New Technology Group 12
  • X2H43MCInsertion of Temporary Intraluminal Device, Venous Angle Decompression using Impeller Pump into Left Innominate Vein, Percutaneous Approach, New Technology Group 12
  • X2HM3GBInsertion of Lumenless Small-diameter Defibrillator Lead into Ventricular Septum, Percutaneous Approach, New Technology Group 11
  • X2HV3GBInsertion of Lumenless Small-diameter Defibrillator Lead into Right Ventricle, Percutaneous Approach, New Technology Group 11
  • X2K00FBBypass Inferior Vena Cava using Autologous Cell Seeded Tissue Engineered Resorbable Scaffold to Pulmonary Artery, Open Approach, New Technology Group 11
  • X2KG0FBBypass Hepatic Vein using Autologous Cell Seeded Tissue Engineered Resorbable Scaffold to Pulmonary Artery, Open Approach, New Technology Group 11
  • X2RF3LCReplacement of Aortic Valve using Zooplastic Tissue, with Integrated Native Leaflet Clipping Locators, Percutaneous Approach, New Technology Group 12
  • X2RG3FCReplacement of Mitral Valve with Balloon-expandable Bioprosthetic Valve with Dock, Percutaneous Approach, New Technology Group 12
  • X2RH0GCReplacement of Pulmonary Valve using Size-Adjustable Synthetic Substitute, Open Approach, New Technology Group 12
  • X2VJ3HCRestriction of Thoracic Aorta, Ascending and Arch using Branched Intraluminal Device, Integrated System with Innominate Branch, Percutaneous Approach, New Technology Group 12
  • X2VW3JCRestriction of Thoracic Aorta, Descending using Branched Intraluminal Device, Integrated System Extension, Percutaneous Approach, New Technology Group 12
  • X2VX0KCRestriction of Thoracic Aorta, Arch using Branched Intraluminal Device, with Conical Collar, Open Approach, New Technology Group 12
  • X9HNew Technology, Ear, Nose, Sinus, Insertion
  • X9HD01BInsertion of Temporary Infusion Device into Right Inner Ear, Open Approach, New Technology Group 11
  • X9HE01BInsertion of Temporary Infusion Device into Left Inner Ear, Open Approach, New Technology Group 11
  • X9HF01BInsertion of Temporary Infusion Device into Bilateral Inner Ear, Open Approach, New Technology Group 11
  • XEZNew Technology, Physiological Systems and Anatomical Regions
  • XEZ5XKCComputer-Aided Triage and Notification for Imaging Abnormalities in Computed Tomography of Chest, Abdomen and Pelvis, New Technology Group 12
  • XEZD3QCPericardial Cavity Access using Blunt-tip Concealed Needle with Mechanical Gripping Mechanism, Percutaneous Approach, New Technology Group 12
  • XEZJ3NCCoronary Artery Access using Image-Guided Crossing and Re-entry System, Percutaneous Approach, New Technology Group 12
  • XEZU3HCComputer-Aided Guidance for Intraprocedural Navigation using Ultrasound Imaging with Continuous Needle Tracking in Spinal Canal, Percutaneous Approach, New Technology Group 12
  • XEZZXJCHigh Dimensional Mixture-of-Experts Computer-aided Assessment of Inflammatory Response and Organ Function, for Notification and Triage, New Technology Group 12
  • XEZZXLCComputer-Aided Detection and Notification for Imaging Abnormalities in Echocardiography, New Technology Group 12
  • XEZZXMCComputer-Aided Detection and Notification for Abnormalities in Electrocardiogram, New Technology Group 12
  • XEZZXPCCardiac Conduction Mechanism, Computer-aided Guidance for Three Dimensional Intraprocedural Navigation using Fluoroscopic Imaging, New Technology Group 12
  • XEZZXRCComputer-Aided Detection and Notification of Cardiac Abnormalities using Vital Signs, New Technology Group 12
  • XEZZXSCCardiac Conduction Mechanism, Computer-aided Intraprocedural Visualization for Guidance, New Technology Group 12
  • XFJB3CCInspection of Hepatobiliary Duct using Single-use Choledochoscope, Percutaneous Approach, New Technology Group 12
  • XFJB4CCInspection of Hepatobiliary Duct using Single-use Choledochoscope, Percutaneous Endoscopic Approach, New Technology Group 12
  • XFJB8BCInspection of Hepatobiliary Duct using Single-use Cholangioscope, Via Natural or Artificial Opening Endoscopic Approach, New Technology Group 12
  • XFJD3CCInspection of Pancreatic Duct using Single-use Choledochoscope, Percutaneous Approach, New Technology Group 12
  • XFJD4CCInspection of Pancreatic Duct using Single-use Choledochoscope, Percutaneous Endoscopic Approach, New Technology Group 12
  • XFJD8BCInspection of Pancreatic Duct using Single-use Cholangioscope, Via Natural or Artificial Opening Endoscopic Approach, New Technology Group 12
  • XHH80JCInsertion of Contractility Modulation Device with Defibrillator Generator into Chest Subcutaneous Tissue and Fascia, Open Approach, New Technology Group 12
  • XRH10NCInsertion of Carbon/PEEK Spinal Stabilization Device into Cervical Vertebral Joint, Open Approach, New Technology Group 12
  • XRH13NCInsertion of Carbon/PEEK Spinal Stabilization Device into Cervical Vertebral Joint, Percutaneous Approach, New Technology Group 12
  • XRH14NCInsertion of Carbon/PEEK Spinal Stabilization Device into Cervical Vertebral Joint, Percutaneous Endoscopic Approach, New Technology Group 12
  • XRH20NCInsertion of Carbon/PEEK Spinal Stabilization Device into 2 or more Cervical Vertebral Joints, Open Approach, New Technology Group 12
  • XRH23NCInsertion of Carbon/PEEK Spinal Stabilization Device into 2 or more Cervical Vertebral Joints, Percutaneous Approach, New Technology Group 12
  • XRH24NCInsertion of Carbon/PEEK Spinal Stabilization Device into 2 or more Cervical Vertebral Joints, Percutaneous Endoscopic Approach, New Technology Group 12
  • XRH40NCInsertion of Carbon/PEEK Spinal Stabilization Device into Cervicothoracic Vertebral Joint, Open Approach, New Technology Group 12
  • XRH43NCInsertion of Carbon/PEEK Spinal Stabilization Device into Cervicothoracic Vertebral Joint, Percutaneous Approach, New Technology Group 12
  • XRH44NCInsertion of Carbon/PEEK Spinal Stabilization Device into Cervicothoracic Vertebral Joint, Percutaneous Endoscopic Approach, New Technology Group 12
  • XRH60NCInsertion of Carbon/PEEK Spinal Stabilization Device into Thoracic Vertebral Joint, Open Approach, New Technology Group 12
  • XRH63NCInsertion of Carbon/PEEK Spinal Stabilization Device into Thoracic Vertebral Joint, Percutaneous Approach, New Technology Group 12
  • XRH64NCInsertion of Carbon/PEEK Spinal Stabilization Device into Thoracic Vertebral Joint, Percutaneous Endoscopic Approach, New Technology Group 12
  • XU7New Technology, Female Reproductive System, Dilation
  • XU7G71BDilation of Vagina with Temporary Electromechanical Intraluminal Device, Via Natural or Artificial Opening, New Technology Group 11
  • XW0134CIntroduction of Elamipretide into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 12
  • XW0330BIntroduction of Alpha1-proteinase Inhibitor into Peripheral Vein, Percutaneous Approach, New Technology Group 11
  • XW0331BIntroduction of Anitocabtagene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 11
  • XW0336CIntroduction of Landiolol Antiarrhythmic into Peripheral Vein, Percutaneous Approach, New Technology Group 12
  • XW0337CIntroduction of Zimislecel Allogeneic Stem Cell-Derived Islet Cell Therapy into Peripheral Vein, Percutaneous Approach, New Technology Group 12
  • XW0430BIntroduction of Alpha1-proteinase Inhibitor into Central Vein, Percutaneous Approach, New Technology Group 11
  • XW0431BIntroduction of Anitocabtagene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 11
  • XW0436CIntroduction of Landiolol Antiarrhythmic into Central Vein, Percutaneous Approach, New Technology Group 12
  • XW0534BIntroduction of Somatic Stem Cells into Peripheral Artery, Percutaneous Approach, New Technology Group 11
  • XW0632BIntroduction of CPI-601 Enzyme Replacement Therapy into Cerebral Ventricle, Percutaneous Approach, New Technology Group 11
  • XW0E33BIntroduction of Lunsotogene Parvec-cwha via Intracochlear Infusion into Ear(s), Percutaneous Approach, New Technology Group 11
  • XW0Q35CIntroduction of Ifezuntirgene Inilparvovec into Cranial Cavity and Brain, Percutaneous Approach, New Technology Group 12
  • XW0U0CCIntroduction of Recombinant Human Bone Morphogenetic Protein-2 with Collagen Scaffold into Joints, Open Approach, New Technology Group 12
  • XW0V0BCIntroduction of Vancomycin-eluting Bone Void Filler into Bones, Open Approach, New Technology Group 12
  • XXE2XHCMeasurement of Cardiac Conduction Mechanism, Computer-aided Mapping for Planning, New Technology Group 12

Revised ICD-10-PCS procedure codes (2)

  • XW0V0P7Introduction of Gentamicin-eluting Bone Void Filler into Bones, Open Approach, New Technology Group 7Was: Introduction of Antibiotic-eluting Bone Void Filler into Bones, Open Approach, New Technology Group 7
  • XW143F8Transfusion of Etuvetidigene Autotemcel into Central Vein, Percutaneous Approach, New Technology Group 8Was: Transfusion of OTL-103 into Central Vein, Percutaneous Approach, New Technology Group 8

Deleted ICD-10-PCS procedure codes (41)

  • 30233AZTransfusion of Embryonic Stem Cells into Peripheral Vein, Percutaneous Approach
  • 30243AZTransfusion of Embryonic Stem Cells into Central Vein, Percutaneous Approach
  • X2KB317Bypass Right Radial Artery using Thermal Resistance Energy, Percutaneous Approach, New Technology Group 7
  • X2KC317Bypass Left Radial Artery using Thermal Resistance Energy, Percutaneous Approach, New Technology Group 7
  • XD2New Technology, Gastrointestinal System, Monitoring
  • XD2G4V7Monitoring of Upper GI Oxygen Saturation, Percutaneous Endoscopic Approach, New Technology Group 7
  • XD2G8V7Monitoring of Upper GI Oxygen Saturation, Via Natural or Artificial Opening Endoscopic, New Technology Group 7
  • XD2H4V7Monitoring of Lower GI Oxygen Saturation, Percutaneous Endoscopic Approach, New Technology Group 7
  • XD2H8V7Monitoring of Lower GI Oxygen Saturation, Via Natural or Artificial Opening Endoscopic, New Technology Group 7
  • XRGA0R7Fusion of Thoracolumbar Vertebral Joint using Custom-Made Anatomically Designed Interbody Fusion Device, Open Approach, New Technology Group 7
  • XRGA3R7Fusion of Thoracolumbar Vertebral Joint using Custom-Made Anatomically Designed Interbody Fusion Device, Percutaneous Approach, New Technology Group 7
  • XRGA4R7Fusion of Thoracolumbar Vertebral Joint using Custom-Made Anatomically Designed Interbody Fusion Device, Percutaneous Endoscopic Approach, New Technology Group 7
  • XRGB0R7Fusion of Lumbar Vertebral Joint using Custom-Made Anatomically Designed Interbody Fusion Device, Open Approach, New Technology Group 7
  • XRGB3R7Fusion of Lumbar Vertebral Joint using Custom-Made Anatomically Designed Interbody Fusion Device, Percutaneous Approach, New Technology Group 7
  • XRGB4R7Fusion of Lumbar Vertebral Joint using Custom-Made Anatomically Designed Interbody Fusion Device, Percutaneous Endoscopic Approach, New Technology Group 7
  • XRGC0R7Fusion of 2 or more Lumbar Vertebral Joints using Custom-Made Anatomically Designed Interbody Fusion Device, Open Approach, New Technology Group 7
  • XRGC3R7Fusion of 2 or more Lumbar Vertebral Joints using Custom-Made Anatomically Designed Interbody Fusion Device, Percutaneous Approach, New Technology Group 7
  • XRGC4R7Fusion of 2 or more Lumbar Vertebral Joints using Custom-Made Anatomically Designed Interbody Fusion Device, Percutaneous Endoscopic Approach, New Technology Group 7
  • XRGD0R7Fusion of Lumbosacral Joint using Custom-Made Anatomically Designed Interbody Fusion Device, Open Approach, New Technology Group 7
  • XRGD3R7Fusion of Lumbosacral Joint using Custom-Made Anatomically Designed Interbody Fusion Device, Percutaneous Approach, New Technology Group 7
  • XRGD4R7Fusion of Lumbosacral Joint using Custom-Made Anatomically Designed Interbody Fusion Device, Percutaneous Endoscopic Approach, New Technology Group 7
  • XW00X27Introduction of Anacaulase-bcdb into Skin, External Approach, New Technology Group 7
  • XW01397Introduction of Satralizumab-mwge into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7
  • XW01X27Introduction of Anacaulase-bcdb into Subcutaneous Tissue, External Approach, New Technology Group 7
  • XW023X7Introduction of Tixagevimab and Cilgavimab Monoclonal Antibody into Muscle, Percutaneous Approach, New Technology Group 7
  • XW03367Introduction of Terlipressin into Peripheral Vein, Percutaneous Approach, New Technology Group 7
  • XW03377Introduction of Trilaciclib into Peripheral Vein, Percutaneous Approach, New Technology Group 7
  • XW03387Introduction of Lurbinectedin into Peripheral Vein, Percutaneous Approach, New Technology Group 7
  • XW033B7Introduction of Amivantamab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 7
  • XW04367Introduction of Terlipressin into Central Vein, Percutaneous Approach, New Technology Group 7
  • XW04377Introduction of Trilaciclib into Central Vein, Percutaneous Approach, New Technology Group 7
  • XW04387Introduction of Lurbinectedin into Central Vein, Percutaneous Approach, New Technology Group 7
  • XW043B7Introduction of Amivantamab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 7
  • XW0DXR7Introduction of Fostamatinib into Mouth and Pharynx, External Approach, New Technology Group 7
  • XW0G7R7Introduction of Fostamatinib into Upper GI, Via Natural or Artificial Opening, New Technology Group 7
  • XW0H7R7Introduction of Fostamatinib into Lower GI, Via Natural or Artificial Opening, New Technology Group 7
  • XW133D7Transfusion of High-Dose Intravenous Immune Globulin into Peripheral Vein, Percutaneous Approach, New Technology Group 7
  • XW133F8Transfusion of OTL-103 into Peripheral Vein, Percutaneous Approach, New Technology Group 8
  • XW143D7Transfusion of High-Dose Intravenous Immune Globulin into Central Vein, Percutaneous Approach, New Technology Group 7
  • XXE5XR7Measurement of Infection, Mechanical Initial Specimen Diversion Technique Using Active Negative Pressure, New Technology Group 7
  • XXE5XT7Measurement of Intracranial Arterial Flow, Whole Blood mRNA, New Technology Group 7